ClinicalTrials.gg
CompletedNCT02709655Updated Sep 22, 2022Results posted

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)

A Phase 3 interventional study of Vortioxetine 10 mg/day and Vortioxetine 20 mg/day in Depressive Disorder, Major, sponsored by H. Lundbeck A/S. Completed at 98 sites in 19 countries. Open to participants aged 7 Years to 11 Years. Per ClinicalTrials.gov, last updated 2022-09-22.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
683
Allocation
Randomized
Ages
7 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
6th of 54
683 · median 413
Started
2016
with 8 others
Phase 3
31 of 54
1 open now
Registered
33rd of 54
by date
Lead sponsor
24 of 54
H. Lundbeck A/S

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 6th largest by enrollment, is one of 9 that started in 2016, is one of 31 in phase 3, and was the 33rd registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 7 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

Investigation of the efficacy and safety of a new potential treatment of Major depressive disorder (MDD) in paediatric participants (age 7 to 11 years).

03

Conditions studied

  • Depressive Disorder, Major

Keywords

  • paediatric
04

Who can participate

Ages eligible
7 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant has MDD, diagnosed according to , 5th Edition (DSM-5™).
  2. The participant has a CDRS-R total score ≥45 at the Screening Visit and the Baseline.
  3. The participant has a CGI-S score ≥4 at the Screening Visit and the Baseline.
  4. The participant is a boy or girl, aged ≥7 and \<12 years at Screening Visit
  5. The participant has provided assent to participation and parent(s)/legal representative (s) signed the Form.

Exclusion criteria

Exclusion Criteria:

  1. The participant has participated in a clinical study \<30 days prior to the Screening Visit.
  2. The participant has previously participated in a study with vortioxetine.

Other protocol defined inclusion and exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
683 participants (actual)

Study arms

  • Experimental
    Vortioxetine 10 mg/day

    Drug: Vortioxetine 10 mg/day

  • Experimental
    Vortioxetine 20 mg/day

    Drug: Vortioxetine 20 mg/day

  • Active comparator
    Fluoxetine 20 mg/day,

    A decision has been taken to stop recruitment into this treatment arm.

    Drug: Fluoxetine 20mg/day

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • DrugVortioxetine 10 mg/day

    Drug page: Vortioxetine

    10 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed

    Also known as: Brintellix ®, Lu AA21004

  • DrugVortioxetine 20 mg/day

    Drug page: Vortioxetine

    20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed

    Also known as: Brintellix ®, Lu AA21004

  • DrugFluoxetine 20mg/day

    Drug page: Fluoxetine

    20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed

  • OtherPlacebo

    Encapsulated tablet, orally

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 8 of Phase B

    The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression). Least square (LS) mean was estimated using a restricted maximum likelihood (REML)-based Mixed Model Repeated Measurements (MMRM) approach.

    Time frame: Baseline (Week 4 of Phase A), Week 8 of Phase B

Secondary outcomes

  1. Change From Baseline in CDRS-R Total Score at Weeks 2, 4, and 6 of Phase B

    The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression).

    Time frame: Baseline (Week 4 of Phase A), Weeks 2, 4, and 6 of Phase B

  2. Change From Baseline in CDRS-R Subscores (Mood, Somatic, Subjective, and Behaviour) at Weeks 2, 4, 6, and 8 of Phase B

    The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression). Four subscores were defined based on the CDRS-R: Mood: sum of items 8, 11, 14, 15; score range 4 to 28, Somatic: sum of items 4, 5, 6, 7, 16, 17; score range 6 to 36, Subjective: sum of items 9, 10, 12, 13; score range 4 to 28, and Behaviour: sum of items 1, 2, 3; score range 3 to 21. Higher scores indicated the most severe measure of depression.

    Time frame: Baseline (Week 4 of Phase A), Weeks 2, 4, 6, and 8 of Phase B

  3. Percentage of Participants With CDRS-R Response

    CDRS-R response was defined as a ≥50% decrease in CDRS-R total score, calculated as: (change from baseline \[Randomization\])/(baseline value - 17). The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression).

    Time frame: Weeks 2, 4, 6, and 8 of Phase B

  4. Percentage of Participants With CDRS-R Remission

    CDRS-R remission was defined as a CDRS-R total score ≤28. The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression).

    Time frame: Weeks 2, 4, 6, and 8 of Phase B

  5. Change From Baseline in General Behaviour Inventory (GBI) Depression Subscale Score, Using the 10-Item Depression Subscale Assessed by Parent (PGBI-10D) and Child (CGBI-10D) at Weeks 2, 4, 6, and 8 of Phase B

    The GBI 10-item depression scale was developed to screen for depressive symptoms in children and adolescents. Two versions of the GBI 10-item depression scale were used, the child rated version (CGBI) and the parent rated version (PGBI). The 10 depression items were rated on a 4-point scale from 0 (never or hardly ever) to 3 (very often or almost constantly). The total score ranged from 0 to 30, with higher scores indicating greater pathology.

    Time frame: Baseline (Week 4 of Phase A), Weeks 2, 4, 6, and 8 of Phase B

  6. Parent Global Assessment (PGA) Score

    The PGA is a parent-rated variation of the CGI-I to evaluate the severity of the child's symptoms. The PGA reflects assessments of symptoms using a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: Weeks 2, 4, 6, and 8 of Phase B

  7. Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score at Weeks 1, 2, 3, 4, 6, and 8 of Phase B

    The CGI-S provides the clinician's impression of the participant's current state of mental illness. The clinician uses his or her clinical experience of this participant population to rate the severity of the participant's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill participants).

    Time frame: Baseline (Week 4 of Phase A), Weeks 1, 2, 3, 4, 6, and 8 of Phase B

  8. Clinical Global Impression - Global Improvement (CGI-I) Score

    The CGI-I provides the clinician's impression of the participant's improvement (or worsening). The clinician assesses the participant's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: Weeks 1, 2, 3, 4, 6, and 8 of Phase B

  9. Percentage of Participants With CGI-S Remission

    CGI-S remission was defined as a CGI-S score of 1 or 2. The CGI-S provides the clinician's impression of the participant's current state of mental illness. The clinician uses his or her clinical experience of this participant population to rate the severity of the participant's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill participants).

    Time frame: Weeks 1, 2, 3, 4, 6, and 8 of Phase B

  10. Change From Baseline in Children's Global Assessment Scale (CGAS) Score at Weeks 4 and 8 of Phase B

    The CGAS is a clinician-rated global scale to measure the lowest level of functioning for a child (4 to 16 years) during a specified time period. The CGAS contains behaviourally-oriented descriptors at each anchor point that depict behaviours and life situations applicable to a child. The score ranges from 1 (most functionally impaired child) to 100 (the healthiest). A score greater than 70 indicates normal function.

    Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

  11. Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score at Weeks 4 and 8 of Phase B

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.

    Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

  12. Change From Baseline in PedsQL VAS: Sad or Blue (Sadness) Score at Weeks 4 and 8 of Phase B

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.

    Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

  13. Change From Baseline in PedsQL VAS: Angry Score at Weeks 4 and 8 of Phase B

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.

    Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

  14. Change From Baseline in PedsQL VAS: Worry Score at Weeks 4 and 8 of Phase B

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.

    Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

  15. Change From Baseline in PedsQL VAS: Tired (Fatigue) Score at Weeks 4 and 8 of Phase B

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.

    Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

  16. Change From Baseline in PedsQL VAS: Pain or Hurt Score at Weeks 4 and 8 of Phase B

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.

    Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

  17. Change From Baseline in PedsQL VAS Total Average Score at Weeks 4 and 8 of Phase B

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL™ VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue, and pain using visual analogue scales. The functionality for each domain is measured on a 10cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. The total score is the average of all 6 items. A lower value represents a better outcome.

    Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

  18. Change From Baseline in PedsQL Emotional Distress Summary Average Score at Weeks 4 and 8 of Phase B

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. The average emotional distress summary score is the mean of the anxiety, sadness, anger, and worry items. A lower value represents a better outcome.

    Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

  19. Change From Baseline in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Score (Items 1 to 14) at Weeks 4 and 8 of Phase B

    The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire, which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1 to 14 assess the degree of satisfaction experienced by participants in various areas of daily functioning, and item 15 allows subjects to summarise their experience in a global rating. Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good). The total score range of item 1 to 14 is 14 to 70, with higher scores indicating greater satisfaction.

    Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

  20. Change From Baseline in PQ-LES-Q Overall Evaluation Score (Item 15) at Weeks 4 and 8 of Phase B

    The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire, which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1 to 14 assess the degree of satisfaction experienced by participants in various areas of daily functioning, and item 15 allows subjects to summarize their experience in a global rating. Item 15 is rated on a 5-point scale from 1 (very poor) to 5 (very good).

    Time frame: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

07

Results

Posted Sep 22, 2022

Participant flow

This study included 2 periods: single-blind (SB) (treatment with standardized brief psychosocial intervention \[BPI\] and placebo) and double-blind (DB) (treatment with BPI and placebo, vortioxetine 10 milligrams \[mg\]/day, vortioxetine 20 mg/day, or fluoxetine 20 mg/day).

Single-Blind Phase (4 Weeks)
Participant flow — Single-Blind Phase (4 Weeks)
MilestoneSingle-Blind: PlaceboDouble-Blind: PlaceboDouble-Blind: Vortioxetine 10 mgDouble-Blind: Vortioxetine 20 mgDouble-Blind: Fluoxetine 20 mg
Started6830000
Received at least 1 dose of study drug6770000
Completed5400000
Not completed1430000
Withdrew: Adverse event20000
Withdrew: Lack of efficacy80000
Withdrew: Non-compliance with study drug30000
Withdrew: Protocol violation30000
Withdrew: Withdrawal by subject150000
Withdrew: Lost to follow-up10000
Withdrew: Failure to meet randomization criteria850000
Withdrew: Other than specified200000
Withdrew: Enrolled but not treated60000
Double-Blind Phase (8 Weeks)
Participant flow — Double-Blind Phase (8 Weeks)
MilestoneSingle-Blind: PlaceboDouble-Blind: PlaceboDouble-Blind: Vortioxetine 10 mgDouble-Blind: Vortioxetine 20 mgDouble-Blind: Fluoxetine 20 mg
Started015315115383
Received at least 1 dose of study drug015315115383
Full analysis set (fas)015314814881
Completed013813513378
Not completed01516205
Withdrew: Adverse event01230
Withdrew: Lack of efficacy02001
Withdrew: Non-compliance with study drug01361
Withdrew: Protocol violation01000
Withdrew: Withdrawal by subject04441
Withdrew: Lost to follow-up01020
Withdrew: Other than specified05752

Outcome measures

PrimaryChange From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 8 of Phase B

The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression). Least square (LS) mean was estimated using a restricted maximum likelihood (REML)-based Mixed Model Repeated Measurements (MMRM) approach.

Time frame:
Baseline (Week 4 of Phase A), Week 8 of Phase B
Reported as:
Least squares mean · units on a scale
Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 8 of Phase B
units on a scaleDouble-Blind: PlaceboDouble-Blind: Vortioxetine 10 mgDouble-Blind: Vortioxetine 20 mgDouble-Blind: Fluoxetine 20 mgVortioxetine Average (Avg. VOR)
Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 8 of Phase B-17.48 ± 1.35-19.20 ± 1.37-19.94 ± 1.37-20.78 ± 1.60-19.57 ± 1.16
Statistical analysis
  • Double-Blind: Placebo vs Vortioxetine Average (Avg. VOR) · Mixed Models Analysis · p = 0.0937 · Mean difference (final values): -2.09 · 95% CI -4.54 to 0.36
  • Double-Blind: Placebo vs Double-Blind: Vortioxetine 10 mg · Mixed Models Analysis · p = 0.2336 · Mean difference (final values): -1.72 · 95% CI -4.56 to 1.11
  • Double-Blind: Placebo vs Double-Blind: Vortioxetine 20 mg · Mixed Models Analysis · p = 0.0879 · Mean difference (final values): -2.46 · 95% CI -5.29 to 0.37
  • Double-Blind: Placebo vs Double-Blind: Fluoxetine 20 mg · Mixed Models Analysis · p = 0.0531 · Mean difference (final values): -3.30 · 95% CI -6.65 to 0.04
SecondaryChange From Baseline in CDRS-R Total Score at Weeks 2, 4, and 6 of Phase B

The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression).

Time frame:
Baseline (Week 4 of Phase A), Weeks 2, 4, and 6 of Phase B
Reported as:
Least squares mean · units on a scale
Change From Baseline in CDRS-R Total Score at Weeks 2, 4, and 6 of Phase B
units on a scaleDouble-Blind: PlaceboDouble-Blind: Vortioxetine 10 mgDouble-Blind: Vortioxetine 20 mgDouble-Blind: Fluoxetine 20 mg
Change at Week 2-9.20 ± 1.17-9.54 ± 1.18-10.30 ± 1.19-10.17 ± 1.32
Change at Week 4-13.15 ± 1.28-14.56 ± 1.30-15.62 ± 1.30-13.97 ± 1.50
Change at Week 6-16.00 ± 1.32-17.64 ± 1.34-18.28 ± 1.34-17.75 ± 1.56
SecondaryChange From Baseline in CDRS-R Subscores (Mood, Somatic, Subjective, and Behaviour) at Weeks 2, 4, 6, and 8 of Phase B

The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression). Four subscores were defined based on the CDRS-R: Mood: sum of items 8, 11, 14, 15; score range 4 to 28, Somatic: sum of items 4, 5, 6, 7, 16, 17; score range 6 to 36, Subjective: sum of items 9, 10, 12, 13; score range 4 to 28, and Behaviour: sum of items 1, 2, 3; score range 3 to 21. Higher scores indicated the most severe measure of depression.

Time frame:
Baseline (Week 4 of Phase A), Weeks 2, 4, 6, and 8 of Phase B
Reported as:
Least squares mean · units on a scale
Change From Baseline in CDRS-R Subscores (Mood, Somatic, Subjective, and Behaviour) at Weeks 2, 4, 6, and 8 of Phase B
units on a scaleDouble-Blind: PlaceboDouble-Blind: Vortioxetine 10 mgDouble-Blind: Vortioxetine 20 mgDouble-Blind: Fluoxetine 20 mg
Mood Score: Change at Week 2-2.82 ± 0.40-3.10 ± 0.40-3.47 ± 0.40-3.02 ± 0.45
Mood Score: Change at Week 4-3.69 ± 0.42-4.39 ± 0.43-4.77 ± 0.43-3.73 ± 0.49
Mood Score: Change at Week 6-4.67 ± 0.43-5.39 ± 0.44-5.52 ± 0.44-4.97 ± 0.51
Mood Score: Change at Week 8-5.08 ± 0.44-5.64 ± 0.44-5.95 ± 0.45-5.84 ± 0.51
Somatic Score: Change at Week 2-2.81 ± 0.44-2.61 ± 0.44-2.88 ± 0.44-3.02 ± 0.50
Somatic Score: Change at Week 4-4.08 ± 0.47-4.30 ± 0.48-4.70 ± 0.48-4.26 ± 0.56
Somatic Score: Change at Week 6-4.86 ± 0.48-5.53 ± 0.49-5.33 ± 0.49-5.57 ± 0.57
Somatic Score: Change at Week 8-5.38 ± 0.49-6.15 ± 0.50-6.08 ± 0.50-6.44 ± 0.57
Subjective Score: Change at Week 2-1.44 ± 0.22-1.46 ± 0.22-1.43 ± 0.22-1.56 ± 0.25
Subjective Score: Change at Week 4-2.04 ± 0.23-2.12 ± 0.23-2.20 ± 0.23-2.17 ± 0.27
Subjective Score: Change at Week 6-2.43 ± 0.24-2.42 ± 0.24-2.65 ± 0.24-2.38 ± 0.28
Subjective Score: Change at Week 8-2.56 ± 0.24-2.59 ± 0.24-2.84 ± 0.24-2.65 ± 0.28
Behaviour Score: Change at Week 2-2.16 ± 0.34-2.40 ± 0.34-2.56 ± 0.35-2.61 ± 0.39
Behaviour Score: Change at Week 4-3.39 ± 0.38-3.77 ± 0.39-4.00 ± 0.39-3.80 ± 0.45
Behaviour Score: Change at Week 6-4.09 ± 0.39-4.31 ± 0.39-4.83 ± 0.40-4.80 ± 0.46
Behaviour Score: Change at Week 8-4.47 ± 0.40-4.80 ± 0.41-5.09 ± 0.41-5.83 ± 0.48
SecondaryPercentage of Participants With CDRS-R Response

CDRS-R response was defined as a ≥50% decrease in CDRS-R total score, calculated as: (change from baseline \[Randomization\])/(baseline value - 17). The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression).

Time frame:
Weeks 2, 4, 6, and 8 of Phase B
Reported as:
Number · percentage of participants
Percentage of Participants With CDRS-R Response
percentage of participantsDouble-Blind: PlaceboDouble-Blind: Vortioxetine 10 mgDouble-Blind: Vortioxetine 20 mgDouble-Blind: Fluoxetine 20 mg
Week 27.810.211.616.3
Week 420.723.426.626.9
Week 630.831.637.233.3
Week 829.436.441.047.4
SecondaryPercentage of Participants With CDRS-R Remission

CDRS-R remission was defined as a CDRS-R total score ≤28. The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression).

Time frame:
Weeks 2, 4, 6, and 8 of Phase B
Reported as:
Number · percentage of participants
Percentage of Participants With CDRS-R Remission
percentage of participantsDouble-Blind: PlaceboDouble-Blind: Vortioxetine 10 mgDouble-Blind: Vortioxetine 20 mgDouble-Blind: Fluoxetine 20 mg
Week 22.05.42.73.8
Week 49.09.510.19.0
Week 614.715.415.314.1
Week 814.716.720.126.9
SecondaryChange From Baseline in General Behaviour Inventory (GBI) Depression Subscale Score, Using the 10-Item Depression Subscale Assessed by Parent (PGBI-10D) and Child (CGBI-10D) at Weeks 2, 4, 6, and 8 of Phase B

The GBI 10-item depression scale was developed to screen for depressive symptoms in children and adolescents. Two versions of the GBI 10-item depression scale were used, the child rated version (CGBI) and the parent rated version (PGBI). The 10 depression items were rated on a 4-point scale from 0 (never or hardly ever) to 3 (very often or almost constantly). The total score ranged from 0 to 30, with higher scores indicating greater pathology.

Time frame:
Baseline (Week 4 of Phase A), Weeks 2, 4, 6, and 8 of Phase B
Reported as:
Least squares mean · units on a scale
Change From Baseline in General Behaviour Inventory (GBI) Depression Subscale Score, Using the 10-Item Depression Subscale Assessed by Parent (PGBI-10D) and Child (CGBI-10D) at Weeks 2, 4, 6, and 8 of Phase B
units on a scaleDouble-Blind: PlaceboDouble-Blind: Vortioxetine 10 mgDouble-Blind: Vortioxetine 20 mgDouble-Blind: Fluoxetine 20 mg
PGBI: Change at Week 2-3.33 ± 0.55-3.38 ± 0.55-3.78 ± 0.56-3.78 ± 0.63
PGBI: Change at Week 4-4.11 ± 0.58-4.72 ± 0.59-5.33 ± 0.59-4.45 ± 0.68
PGBI: Change at Week 6-5.32 ± 0.58-5.58 ± 0.59-5.82 ± 0.59-6.05 ± 0.68
PGBI: Change at Week 8-5.81 ± 0.61-6.51 ± 0.62-6.46 ± 0.62-6.56 ± 0.72
CGBI: Change at Week 2-2.66 ± 0.61-3.32 ± 0.61-3.27 ± 0.61-2.94 ± 0.70
CGBI: Change at Week 4-3.65 ± 0.65-4.15 ± 0.65-4.16 ± 0.65-3.16 ± 0.76
CGBI: Change at Week 6-4.62 ± 0.63-5.43 ± 0.64-5.17 ± 0.63-5.14 ± 0.73
CGBI: Change at Week 8-5.26 ± 0.65-6.12 ± 0.66-5.48 ± 0.65-5.46 ± 0.76
SecondaryParent Global Assessment (PGA) Score

The PGA is a parent-rated variation of the CGI-I to evaluate the severity of the child's symptoms. The PGA reflects assessments of symptoms using a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

Time frame:
Weeks 2, 4, 6, and 8 of Phase B
Reported as:
Least squares mean · units on a scale
Parent Global Assessment (PGA) Score
units on a scaleDouble-Blind: PlaceboDouble-Blind: Vortioxetine 10 mgDouble-Blind: Vortioxetine 20 mgDouble-Blind: Fluoxetine 20 mg
Week 23.31 ± 0.093.25 ± 0.093.18 ± 0.093.13 ± 0.11
Week 42.97 ± 0.102.90 ± 0.102.84 ± 0.102.90 ± 0.12
Week 62.73 ± 0.102.73 ± 0.102.68 ± 0.102.80 ± 0.12
Week 82.68 ± 0.112.62 ± 0.112.61 ± 0.112.59 ± 0.13
SecondaryChange From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score at Weeks 1, 2, 3, 4, 6, and 8 of Phase B

The CGI-S provides the clinician's impression of the participant's current state of mental illness. The clinician uses his or her clinical experience of this participant population to rate the severity of the participant's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill participants).

Time frame:
Baseline (Week 4 of Phase A), Weeks 1, 2, 3, 4, 6, and 8 of Phase B
Reported as:
Least squares mean · units on a scale
Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score at Weeks 1, 2, 3, 4, 6, and 8 of Phase B
units on a scaleDouble-Blind: PlaceboDouble-Blind: Vortioxetine 10 mgDouble-Blind: Vortioxetine 20 mgDouble-Blind: Fluoxetine 20 mg
Change at Week 1-0.25 ± 0.07-0.27 ± 0.07-0.28 ± 0.07-0.22 ± 0.08
Change at Week 2-0.50 ± 0.08-0.60 ± 0.08-0.65 ± 0.08-0.63 ± 0.10
Change at Week 3-0.67 ± 0.08-0.62 ± 0.08-0.79 ± 0.08-0.77 ± 0.10
Change at Week 4-0.95 ± 0.09-1.00 ± 0.09-1.06 ± 0.09-1.01 ± 0.12
Change at Week 6-1.13 ± 0.10-1.22 ± 0.10-1.27 ± 0.10-1.23 ± 0.12
Change at Week 8-1.31 ± 0.10-1.40 ± 0.11-1.44 ± 0.11-1.57 ± 0.13
SecondaryClinical Global Impression - Global Improvement (CGI-I) Score

The CGI-I provides the clinician's impression of the participant's improvement (or worsening). The clinician assesses the participant's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).

Time frame:
Weeks 1, 2, 3, 4, 6, and 8 of Phase B
Reported as:
Least squares mean · units on a scale
Clinical Global Impression - Global Improvement (CGI-I) Score
units on a scaleDouble-Blind: PlaceboDouble-Blind: Vortioxetine 10 mgDouble-Blind: Vortioxetine 20 mgDouble-Blind: Fluoxetine 20 mg
Week 13.66 ± 0.073.63 ± 0.073.60 ± 0.073.72 ± 0.08
Week 23.32 ± 0.083.30 ± 0.083.19 ± 0.083.26 ± 0.10
Week 33.20 ± 0.083.20 ± 0.083.14 ± 0.083.23 ± 0.10
Week 42.93 ± 0.092.93 ± 0.092.82 ± 0.092.97 ± 0.11
Week 62.70 ± 0.092.64 ± 0.102.65 ± 0.102.78 ± 0.12
Week 82.69 ± 0.102.58 ± 0.082.60 ± 0.102.57 ± 0.12
SecondaryPercentage of Participants With CGI-S Remission

CGI-S remission was defined as a CGI-S score of 1 or 2. The CGI-S provides the clinician's impression of the participant's current state of mental illness. The clinician uses his or her clinical experience of this participant population to rate the severity of the participant's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill participants).

Time frame:
Weeks 1, 2, 3, 4, 6, and 8 of Phase B
Reported as:
Number · percentage of participants
Percentage of Participants With CGI-S Remission
percentage of participantsDouble-Blind: PlaceboDouble-Blind: Vortioxetine 10 mgDouble-Blind: Vortioxetine 20 mgDouble-Blind: Fluoxetine 20 mg
Week 100.700
Week 20.73.41.43.7
Week 33.34.14.77.4
Week 48.58.112.812.3
Week 614.416.216.214.8
Week 822.922.320.929.6
SecondaryChange From Baseline in Children's Global Assessment Scale (CGAS) Score at Weeks 4 and 8 of Phase B

The CGAS is a clinician-rated global scale to measure the lowest level of functioning for a child (4 to 16 years) during a specified time period. The CGAS contains behaviourally-oriented descriptors at each anchor point that depict behaviours and life situations applicable to a child. The score ranges from 1 (most functionally impaired child) to 100 (the healthiest). A score greater than 70 indicates normal function.

Time frame:
Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Reported as:
Least squares mean · units on a scale
Change From Baseline in Children's Global Assessment Scale (CGAS) Score at Weeks 4 and 8 of Phase B
units on a scaleDouble-Blind: PlaceboDouble-Blind: Vortioxetine 10 mgDouble-Blind: Vortioxetine 20 mgDouble-Blind: Fluoxetine 20 mg
Change at Week 48.93 ± 1.239.84 ± 1.258.73 ± 1.2610.54 ± 1.39
Change at Week 812.71 ± 1.3112.98 ± 1.3313.22 ± 1.3416.35 ± 1.51
SecondaryChange From Baseline in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score at Weeks 4 and 8 of Phase B

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.

Time frame:
Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Reported as:
Least squares mean · units on a scale
Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score at Weeks 4 and 8 of Phase B
units on a scaleDouble-Blind: PlaceboDouble-Blind: Vortioxetine 10 mgDouble-Blind: Vortioxetine 20 mgDouble-Blind: Fluoxetine 20 mg
Change at Week 4-0.48 ± 0.27-0.51 ± 0.27-0.48 ± 0.27-0.41 ± 0.31
Change at Week 8-0.73 ± 0.26-1.07 ± 0.27-1.01 ± 0.27-1.08 ± 0.29
SecondaryChange From Baseline in PedsQL VAS: Sad or Blue (Sadness) Score at Weeks 4 and 8 of Phase B

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.

Time frame:
Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Reported as:
Least squares mean · units on a scale
Change From Baseline in PedsQL VAS: Sad or Blue (Sadness) Score at Weeks 4 and 8 of Phase B
units on a scaleDouble-Blind: PlaceboDouble-Blind: Vortioxetine 10 mgDouble-Blind: Vortioxetine 20 mgDouble-Blind: Fluoxetine 20 mg
Change at Week 4-1.20 ± 0.31-1.65 ± 0.31-1.78 ± 0.31-1.42 ± 0.35
Change at Week 8-1.72 ± 0.32-2.23 ± 0.32-2.05 ± 0.32-2.31 ± 0.36
SecondaryChange From Baseline in PedsQL VAS: Angry Score at Weeks 4 and 8 of Phase B

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.

Time frame:
Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Reported as:
Least squares mean · units on a scale
Change From Baseline in PedsQL VAS: Angry Score at Weeks 4 and 8 of Phase B
units on a scaleDouble-Blind: PlaceboDouble-Blind: Vortioxetine 10 mgDouble-Blind: Vortioxetine 20 mgDouble-Blind: Fluoxetine 20 mg
Change at Week 4-0.98 ± 0.30-1.36 ± 0.31-1.33 ± 0.31-1.22 ± 0.35
Change at Week 8-1.24 ± 0.31-1.98 ± 0.32-1.36 ± 0.32-1.67 ± 0.36
SecondaryChange From Baseline in PedsQL VAS: Worry Score at Weeks 4 and 8 of Phase B

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.

Time frame:
Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Reported as:
Least squares mean · units on a scale
Change From Baseline in PedsQL VAS: Worry Score at Weeks 4 and 8 of Phase B
units on a scaleDouble-Blind: PlaceboDouble-Blind: Vortioxetine 10 mgDouble-Blind: Vortioxetine 20 mgDouble-Blind: Fluoxetine 20 mg
Change at Week 4-0.63 ± 0.31-1.48 ± 0.32-1.21 ± 0.32-1.27 ± 0.36
Change at Week 8-1.08 ± 0.32-1.82 ± 0.33-1.45 ± 0.33-1.41 ± 0.36
SecondaryChange From Baseline in PedsQL VAS: Tired (Fatigue) Score at Weeks 4 and 8 of Phase B

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.

Time frame:
Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Reported as:
Least squares mean · units on a scale
Change From Baseline in PedsQL VAS: Tired (Fatigue) Score at Weeks 4 and 8 of Phase B
units on a scaleDouble-Blind: PlaceboDouble-Blind: Vortioxetine 10 mgDouble-Blind: Vortioxetine 20 mgDouble-Blind: Fluoxetine 20 mg
Change at Week 4-1.22 ± 0.34-1.19 ± 0.35-1.63 ± 0.35-0.94 ± 0.39
Change at Week 8-1.39 ± 0.36-1.32 ± 0.37-1.74 ± 0.37-1.73 ± 0.41
SecondaryChange From Baseline in PedsQL VAS: Pain or Hurt Score at Weeks 4 and 8 of Phase B

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome.

Time frame:
Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Reported as:
Least squares mean · units on a scale
Change From Baseline in PedsQL VAS: Pain or Hurt Score at Weeks 4 and 8 of Phase B
units on a scaleDouble-Blind: PlaceboDouble-Blind: Vortioxetine 10 mgDouble-Blind: Vortioxetine 20 mgDouble-Blind: Fluoxetine 20 mg
Change at Week 4-0.22 ± 0.28-0.81 ± 0.28-0.45 ± 0.28-0.50 ± 0.32
Change at Week 8-0.70 ± 0.28-0.79 ± 0.28-1.02 ± 0.28-0.69 ± 0.32
SecondaryChange From Baseline in PedsQL VAS Total Average Score at Weeks 4 and 8 of Phase B

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL™ VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue, and pain using visual analogue scales. The functionality for each domain is measured on a 10cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. The total score is the average of all 6 items. A lower value represents a better outcome.

Time frame:
Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Reported as:
Least squares mean · units on a scale
Change From Baseline in PedsQL VAS Total Average Score at Weeks 4 and 8 of Phase B
units on a scaleDouble-Blind: PlaceboDouble-Blind: Vortioxetine 10 mgDouble-Blind: Vortioxetine 20 mgDouble-Blind: Fluoxetine 20 mg
Change at Week 4-0.81 ± 0.19-1.19 ± 0.19-1.17 ± 0.20-1.01 ± 0.22
Change at Week 8-1.17 ± 0.20-1.55 ± 0.20-1.47 ± 0.20-1.54 ± 0.23
SecondaryChange From Baseline in PedsQL Emotional Distress Summary Average Score at Weeks 4 and 8 of Phase B

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. The average emotional distress summary score is the mean of the anxiety, sadness, anger, and worry items. A lower value represents a better outcome.

Time frame:
Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Reported as:
Least squares mean · units on a scale
Change From Baseline in PedsQL Emotional Distress Summary Average Score at Weeks 4 and 8 of Phase B
units on a scaleDouble-Blind: PlaceboDouble-Blind: Vortioxetine 10 mgDouble-Blind: Vortioxetine 20 mgDouble-Blind: Fluoxetine 20 mg
Change at Week 4-0.84 ± 0.21-1.28 ± 0.21-1.22 ± 0.22-1.13 ± 0.24
Change at Week 8-1.22 ± 0.22-1.80 ± 0.22-1.51 ± 0.22-1.66 ± 0.25
SecondaryChange From Baseline in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Score (Items 1 to 14) at Weeks 4 and 8 of Phase B

The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire, which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1 to 14 assess the degree of satisfaction experienced by participants in various areas of daily functioning, and item 15 allows subjects to summarise their experience in a global rating. Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good). The total score range of item 1 to 14 is 14 to 70, with higher scores indicating greater satisfaction.

Time frame:
Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Reported as:
Least squares mean · units on a scale
Change From Baseline in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Score (Items 1 to 14) at Weeks 4 and 8 of Phase B
units on a scaleDouble-Blind: PlaceboDouble-Blind: Vortioxetine 10 mgDouble-Blind: Vortioxetine 20 mgDouble-Blind: Fluoxetine 20 mg
Change at Week 43.94 ± 0.954.90 ± 0.964.90 ± 0.974.36 ± 1.09
Change at Week 86.22 ± 0.987.08 ± 0.997.14 ± 1.006.79 ± 1.12
SecondaryChange From Baseline in PQ-LES-Q Overall Evaluation Score (Item 15) at Weeks 4 and 8 of Phase B

The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire, which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1 to 14 assess the degree of satisfaction experienced by participants in various areas of daily functioning, and item 15 allows subjects to summarize their experience in a global rating. Item 15 is rated on a 5-point scale from 1 (very poor) to 5 (very good).

Time frame:
Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B
Reported as:
Least squares mean · units on a scale
Change From Baseline in PQ-LES-Q Overall Evaluation Score (Item 15) at Weeks 4 and 8 of Phase B
units on a scaleDouble-Blind: PlaceboDouble-Blind: Vortioxetine 10 mgDouble-Blind: Vortioxetine 20 mgDouble-Blind: Fluoxetine 20 mg
Change at Week 40.28 ± 0.090.37 ± 0.090.43 ± 0.090.24 ± 0.11
Change at Week 80.41 ± 0.090.49 ± 0.090.52 ± 0.090.45 ± 0.11

Adverse events

Collected over Baseline up to Week 16. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single-Blind: Placebo0/677 (0%)6/677 (0.9%)106/677 (15.7%)
Double-Blind: Placebo0/153 (0%)3/153 (2%)45/153 (29.4%)
Double-Blind: Vortioxetine 10 mg0/151 (0%)1/151 (0.7%)55/151 (36.4%)
Double-Blind: Vortioxetine 20 mg0/153 (0%)2/153 (1.3%)42/153 (27.5%)
Double-Blind: Fluoxetine 20 mg0/83 (0%)1/83 (1.2%)27/83 (32.5%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventSingle-Blind: PlaceboDouble-Blind: PlaceboDouble-Blind: Vortioxetine 10 mgDouble-Blind: Vortioxetine 20 mgDouble-Blind: Fluoxetine 20 mg
Forearm fractureInjury, poisoning and procedural complications0/6770/1530/1510/1531/83
TracheitisInfections and infestations0/6770/1531/1510/1530/83
Suicide attemptPsychiatric disorders1/6771/1530/1510/1530/83
CellulitisInfections and infestations0/6771/1530/1510/1530/83
PneumoniaInfections and infestations0/6771/1530/1510/1530/83
Major depressionPsychiatric disorders0/6770/1530/1511/1530/83
ManiaPsychiatric disorders0/6770/1530/1511/1530/83
TachycardiaCardiac disorders1/6770/1530/1510/1530/83
GastroenteritisInfections and infestations1/6770/1530/1510/1530/83
Viral pharyngitisInfections and infestations1/6770/1530/1510/1530/83
Most frequent other events
Showing 10 of 15
Most frequent other events
EventSingle-Blind: PlaceboDouble-Blind: PlaceboDouble-Blind: Vortioxetine 10 mgDouble-Blind: Vortioxetine 20 mgDouble-Blind: Fluoxetine 20 mg
NauseaGastrointestinal disorders23/6777/15319/15117/1535/83
HeadacheNervous system disorders39/67717/15314/15114/1534/83
VomitingGastrointestinal disorders13/6773/15314/15110/1533/83
Abdominal painGastrointestinal disorders9/6772/1539/1516/1532/83
DizzinessNervous system disorders9/6775/1537/1515/1533/83
NasopharyngitisInfections and infestations13/6775/1536/1514/1533/83
Abdominal pain upperGastrointestinal disorders15/6774/1534/1513/1533/83
DiarrhoeaGastrointestinal disorders9/6774/1535/1511/1533/83
Decreased appetiteMetabolism and nutrition disorders0/6772/1531/1512/1533/83
IllnessGeneral disorders0/6770/1530/1515/1530/83

Baseline characteristics

All-patients-treated set Phase A (APTS_A) included all participants enrolled to the 4-week Single-blind period (Phase A) who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Single-Blind: Placebo
Mean9.3 ± 1.42
Sex: Female, Male
Sex: Female, Male(Participants)Single-Blind: Placebo
Female312
Male365
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Single-Blind: Placebo
Race — American Indian or Alaska Native1
Race — Asian2
Race — Black or African American112
Race — Not Reported12
Race — Other229
Race — White321
Children Depression Rating Scale - Revised (CDRS-R) Total Score
Children Depression Rating Scale - Revised (CDRS-R) Total Score(units on a scale)Single-Blind: Placebo
Mean63.4 ± 9.12
08

Study locations

98 sites
  • Woodland International Research Group
    Little Rock, Arkansas 72211, United States
  • Sun Valley Research Center
    Imperial, California 92251, United States
  • Synergy Clinical Research Center
    Lemon Grove, California 91945, United States
  • Alliance for Wellness dba Alliance for Research
    Long Beach, California 90807, United States
  • NRC Research Institute
    Orange, California 92868, United States
  • Asclepes Research Center
    Panorama City, California 91402, United States
  • Children's National Medical Center Merge
    Washington, District of Columbia 20010, United States
  • Sarkis Clinical Trials
    Gainesville, Florida 32607, United States
  • Medical Research Group of Central Florida
    Orange City, Florida 32763, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Northwest Behavioral Research Center
    Marietta, Georgia 30060, United States
  • American Medical Research, Inc.
    Chicago, Illinois 60612, United States
  • AMR- Baber Research, Inc.
    Naperville, Illinois 60563, United States
  • AMR Conventions Research
    Warrenville, Illinois 60555, United States
  • Kansas University School of Medicine-Wichita
    Wichita, Kansas 67214, United States
  • Lake Charles Clinical Trials
    Lake Charles, Louisiana 70629, United States
  • Kennedy Krieger Institute
    Baltimore, Maryland 21205, United States
  • St. Charles Psychiatric Associates - Midwest Research Group
    Saint Charles, Missouri 63304, United States
  • Millennium Psychiatric Associates, LLC
    Saint Louis, Missouri 63132, United States
  • Princeton Medical Institute
    Princeton, New Jersey 08540, United States
  • Manhattan Behavioral Medicine
    New York, New York 10036, United States
  • Finger Lakes Clinical Research
    Rochester, New York 14618, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45219, United States
  • University Hospital Cleveland Medical Center Division of Child and Adolescent Psychiatry
    Cleveland, Ohio 44012, United States
  • North Star Medical Research, LLC
    Middleburg Heights, Ohio 44130, United States
  • IPS Research Company
    Oklahoma City, Oklahoma 73106, United States
  • Paradigm Research Professionals, LLC
    Oklahoma City, Oklahoma 73118, United States
  • Research Strategies Of Memphis, Llc
    Memphis, Tennessee 38119, United States
  • BioBehavioral Research of Austin
    Austin, Texas 78759, United States
  • AIM Trials, LLC
    Plano, Texas 75093, United States
  • Research Across America
    Plano, Texas 75093, United States
  • Clinical Trials of Texas, Inc.
    San Antonio, Texas 78229, United States
  • Westside Medical
    Clinton, Utah 84015, United States
  • Aspen Clinical Research, LLC
    Orem, Utah 84058, United States
  • MHAT Targovishte AD
    Targovisthe, 7700, Bulgaria
  • Diagnostic Consultative Center Mladost-M Varna OOD
    Varna, 9020, Bulgaria
  • Paediatric Sleep Research Inc.
    Toronto, Ontario M5S 3A3, Canada
  • E.S.E. Hospital Mental de Antioquia HOMO
    Bello, Antioquia 51050, Colombia
  • Centro de Investigaciones y Proyectos en Neurociencias CIPNA LTDA IPS.
    Barranquilla, Atlantico 80020, Colombia
  • Centro de investigaciones del Sistema Nervioso SAS Grupo CISNE SAS
    Bogota, DC 111166, Colombia
  • Psynapsis Salud Mental S.A.
    Pereira, Risaralda, Colombia
  • Marienthali Kliinik
    Tallinn, 11315, Estonia
  • Cabinet Psyche
    Douai, Nord 59500, France
  • Centre Medical Ambroise Pare
    Elancourt, 78990, France
  • CHU de Nantes - Hopital Hotel Dieu
    Nantes Cedex 1, 44093, France
  • Rheinhessen-Fachklinik Mainz, Kinder und Jugendpsychiatri
    Mainz, 55122, Germany
  • Vadaskert Alapitvany
    Budapest, 1021, Hungary
  • Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza
    Gyula, 5700, Hungary
  • Shalvata Mental Health Center
    Hod Hasharon, 4534708, Israel
  • Ramat Chen - Mental Health Clinic
    Tel Aviv, 6435807, Israel
  • The Chaim Sheba Medical Center - The Edmond and Lily Safra Children's Hospital
    Tel Hashomer, 5262000, Israel
  • Scientific Institute Fondazione Stella Maris
    Calambrone Pisa, Pisa 56026, Italy
  • Sciaf Ulss 16 Padova
    Padova, Regione Veneto 35143, Italy
  • University Federico II Of Naples
    Napoli, 80131, Italy
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Linda Keruze's Psychiatric Center, LLC
    Liepaja, LV-3401, Latvia
  • Children Hospilal -Gailezers
    Riga, 1079, Latvia
  • Instituto Nacional de Pediatria (INP) (National Institute of Pediatrics)
    Ciudad de Mexico, Distrito Federal 04530, Mexico
  • Centro Investigacion Medico Biologica Y Terapia Avanzada
    Guadalajara, Jalisco 44130, Mexico
  • Clinica Cemelli
    Guadalajara, Jalisco 44200, Mexico
  • Roberto Zepeda Sanchez
    Guadalajara, Jalisco 44690, Mexico
  • CRI Centro Regiomontano de Investigacion SC
    Monterrey, Nuevo Leon 64060, Mexico
  • Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada S.C
    Culiacan De Rosales, Sinaloa 80230, Mexico
  • B & B Investigaciones Medicas, SC
    Mazatlan, Sinaloa 82140, Mexico
  • ICARO Investigaciones en Medicina S.A. de C.V.
    Chihuahua, 31000, Mexico
  • BIND Investigaciones S.C
    San Luis Potosi, 78213, Mexico
  • Prywatne Gabinety Lekarskie Promedicus
    Bialystok, Podlaskie 15879, Poland
  • Centrum Badan Klinicznych PI-House Sp. z o.o.
    Gdansk, 80-546, Poland
  • Przychodnia Syntonia Poradnia Zdrowia Psychicznego
    Kielce, 25-103, Poland
  • Spectrum Centrum Psychiatrii Specjalistyczny Gabinet Psychiatryczny
    Lublin, 20-884, Poland
  • Filip Rybakowski Specjalistyczna Praktyka Lekarska
    Poznan, 60-744, Poland
  • Specjalistyczny Szpital im. dra A. Sokolowskiego w Walbrzychu
    Walbrzych, 58300, Poland
  • Medicorehabilitation Research Center Phoenix
    Rostov-On-Don, Rostov State 344010, Russian Federation
  • Stavropol Region Psychiatric Hospital No.2
    Stavropol, Stavropol Region 357034, Russian Federation
  • Arkhangelsk Regional Clinical Mental Hospital
    Arkhangelsk, 163530, Russian Federation
  • State Budgetary Healthcare Institution of Sverdlovsk Region ¿Sverdlovsk Regional Clinical Psychi...
    Ekaterinburg, 620030, Russian Federation
  • GUZ Engels Psychiatric Hospital
    Engels, 413124, Russian Federation
  • State Budgetary Healthcare Institution (SBHI) Specialized Clinical Psychiatric Hospital 1 of the ...
    Krasnodar, 350007, Russian Federation
  • LLC City Neurological Center Sibneuromed
    Novosibirsk, 630091, Russian Federation
  • Rostov State Medical University of the Minzdravsotsrazvitiya of Russia
    Rostov-on-Don, 344022, Russian Federation
  • Saratov State Medical University
    Saratov, 410028, Russian Federation
  • Guz Saratov Regional Psychiatric Hospital St. Sofii
    Saratov, 410060, Russian Federation
  • City Psychiatric Hospital No.3 named after I.I. Skvortsov-Stepanov
    St-Petersburg, 197341, Russian Federation
  • Nebbiolo LLC
    Tomsk, 634009, Russian Federation
  • Yaroslavl Regional Clinical Psychiatry Hospital
    Yaroslavl, 150003, Russian Federation
  • Child and Adolescent Neurology and Psychiatry Clinic
    Belgrade, 11000, Serbia
  • Institute of Mental Health
    Belgrade, 11000, Serbia
  • University Clinical Center Kragujevac
    Kragujevac, 34000, Serbia
  • Clinical Center of Vojvodina - Clinic of Psychiatry
    Novi Sad, 21000, Serbia
  • Daily Hospital for Children and Adolescents
    Pantelej-Nis, 18000, Serbia
  • Cape Trial Centre
    Bellville, Cape Town 7530, South Africa
  • Tara Hospital
    Sandhurst, Gauteng 2196, South Africa
  • Hospital Universitario Fundacion Alcorcon
    Alcorcon, Madrid 28922, Spain
  • Unidad de Salud Mental Infanto-Juvenil (USMI-J) Edificio de Consultas Externas. Hospital MarAtimo
    Torremolinos, Malaga 29620, Spain
  • Ukrainian Research Institute Of Social, Forensic Psychiatry And Drug Abuse, Kiev City Psychoneuro...
    Kyiv, 04080, Ukraine
  • Odessa Regional Medical Centre of Mental Health
    Odessa, 65006, Ukraine
  • Maltsev Poltava Regional Clinical Psychiatric Hospital, Higher State Educational Institution Of U...
    Poltava, 36013, Ukraine
  • Ternopil Regional Clinical Municipal Psycho-Neurological Hospital, Ternopil State Medical Univers...
    Ternopil, 46000, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Jan 2022, 68 months.

Results were first posted in Sep 2022, 8 months after primary completion.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 68 months is above that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2016
First posted
Mar 16, 2016
StartActual
May 18, 2016
Primary completionActual
Jan 21, 2022
CompletionActual
Jan 21, 2022
Results first posted
Sep 22, 2022
Last update
Sep 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02709655
Lead sponsor
H. Lundbeck A/S
Collaborators
Takeda
Responsible party
Sponsor
First posted
Mar 16, 2016
Start date
May 18, 2016
Primary completion
Jan 21, 2022
Completion
Jan 21, 2022
Results posted
Sep 22, 2022
Last update
Sep 22, 2022

Study contacts

Email contact via Lundbeck A/S
study director · LundbeckClinicalTrials@Lundbeck.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion